Influenza Vaccine | Whitepaper

Highlights in this white paper include:

This paper evaluates the methods manufacturers pursued in response to the swine flu pandemic 0f 2009/2010. It includes an analysis of alternate manufacturing methods and routes of administration, encompassing approved vaccines and trial metrics, to identify how manufacturers addressed these issues and how effective they have been.

Companies developing cell culture manufactured influenza vaccines
Status of trivalent and quadrivalent vaccines including manufacturing processes and delivery routes
Current landscape in quadivalent vaccine development
Intradermal and subcutaneous influenza vaccine trials by phase
How processes surrounding influenza production have changed since the 2009/10 H1N1
influenza pandemic, and what this tells us about how manufacturers are positioned to deal with new influenza strains